explore -WSS

explore

author：knowledge 2025-09-27 09:37:59 - browse：2

An light blue number 3 with an eye is surrounded by smaller, black number 3s on an orange background — 3 to watch coverage from STAT — Christine Kao/STAT

It’s been a slow year for medtech. Major deals in 2023 were scarce, funding was hard to come by, and valuations were down. On the policy side, the industry grappled with changing AI regulations, reimbursement woes, and device sterilization rules.

Here are three political and market forces that shaped the medtech industry last year, and are worth paying attention to in 2024:

Lobbying power of AI, software-enabled devices

Medtech lobby AdvaMed announced earlier this month that the major medical imaging companies, previously housed within the National Electrical Manufacturers Association, were shifting to their shop. The device group also created a separate niche for digital health companies in October.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： With measles on the rise, a personal story of a devastating disease

WSS

HIV vaccine remains elusive. Immunologists keep trying new ideas

Making AI in medicine accessible to smaller, and rural hospitals

Venture capitalist Bob Kocher on the state of digital health

First recipient of genetically engineered pig kidney has died

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

Solving academic medical centers' existential crisis

focus

explore

Lobbying power of AI, software-enabled devices

knowledge

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readers respond to H5N1 and livestock movements, and more

The cancer drug shortage isn’t new — and neither are the solutions

Google says AlphaFold 3 can map a vast universe of biomolecules

Hepatitis C has a cure — but many Americans still lack access to it

Readout LOUD podcast: What to know about H5N1 bird flu

Hepatitis C has a cure — but many Americans still lack access to it

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

Guidelines to prevent youth baseball injuries need more muscle

Case highlights the risks of experimental stem cell therapy

hotspot

Elevance, private equity launch primary care company

Data integrity in scientific journals requires "effort" by publishers, institutions

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Cytokinetics CEO stresses company can launch heart drug on its own

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

focus

focus

explore

knowledge